Date: 2013-01-09
Type of information: Fundraising
Company: Spinomix (Switzerland)
Investors: Debiopharm Group™ (Switzerland) existing investors undisclosed private US investor group
Amount: $ 3 million (€2.3 million)
Funding type: series A financing round
Planned used: Spinomix focuses on delivering high-quality-low-cost solutions for sample preparation of biological materials. The extraction and concentration of targeted cells and molecules (e.g. bacteria and DNA) under routine conditions, of adequate quality and at optimal cost are critical for their detection on existing and future in vitro diagnostic platforms. Spinomix’s approaches use two proprietary technologies: MagPhase™, an automated sample preparation platform based on magnetic nanoparticles and microfluidics with cost efficient, rapidly processed and disposable cartridges. FibroTrap™, a fibrinogen based technology, to separate targeted cells and molecules within routine sample collection tubes. The funds allow Spinomix to consolidate its development pipeline and to strengthen existing and new in vitro diagnostic industry collaborations.
Others: Spinomix, a Swiss company advancing molecular diagnostic technologies, has closed a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group™. Significant participation and support is being provided by existing investors and a private US investor group with proven entrepreneurial experience.
The company has also recruited a new CEO, Nasri Nahas. Over the course of his 12 years tenure as the CEO of Geneva Bioinformatics (GeneBio) SA, he has led GeneBio’s operations and successfully built an exceptional and highly motivated team of industry experts who grew the company from a start-up-like setting to an experienced, well-established and renowned organization.
Therapeutic area: Diagnostic